View source for Abciximab

==Administration==
*Type: Glycoprotein IIB/IIIA inhibitor, [[antiplatelet]]
*Dosage Forms: Injection
*Routes of Administration: IV
*Common Trade Names: Reopro

==Adult Dosing==
===PCI Adjunct===
*0.125 mcg/kg/min IV x 12h
**Part of multidrug regiment with [[heparin]] and [[aspirin]]
===[[Unstable angina]], refractory===
*10 mcg/min IV x 18-24h
**Part of multidrug regiment with [[heparin]] and [[aspirin]]

==Pediatric Dosing==
Safety/efficacy not established in pediatric patients

==Special Populations==
===[[Drug pregnancy categories|Pregnancy Rating]]===
*Benefits outweigh risks during pregnancy
*Inadequate human data available to assess risk
*Risk of maternal hemorrhage during delivery

===Lactation risk===
*May use while breast feeding

===Renal Dosing===
*Adult: Not defined
*Pediatric: Unavailable

===Hepatic Dosing===
*Adult: Not defined
*Pediatric: Unavailable

==Contraindications==
*Allergy to class/drug
*Hypersensitivity to murine proteins
*Active internal bleeding
*GI/GU bleeding w/in 6 weeks
*[[Stroke]] w/in 2 years
*Coagulation disorder
*Plt < 100,000
*INR > 1.2
*Recent surgery or trauma
*[[HTN]], uncontrolled
*Intracranial neoplasm, AVM, or aneurysm
*[[Vasculitis]] hx
*Dextran use in coronary procedure

==Adverse Reactions==
===Serious===
*[[Thrombocytopenia]]
*Bleeding
*[[AV Block]], complete
*[[Anaphylaxis]]

===Common===
*Bleeding, [[hypotension]]
*Back pain, chest pain, abdominal pain
*Peripheral edema
*[[Nausea]], [[vomiting]]
*[[Headache]], [[dizziness]]
*[[Bradycardia]]

==Pharmacology==
*Half-life: <10 min initially then 30 min second phase
*Metabolism: Other
*Excretion: Urine

==Mechanism of Action==
*Binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation

==Comments==


==See Also==
*[[Antiplatelet medications]]
*[[Antiplatelet agent reversal]]

==References==
*Aguirre FV, Topol EJ, and Ferguson JJ, “Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Intergrin in Patients Undergoing Percutaneous Coronary Intervention. EPIC Investigators,” Circulation, 1995, 91(12):2882-90. [PubMed 7796496]
*Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. [PubMed 25260718
*Antman EM, Giugliano RP, Gibson CM, et al, “Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,” Circulation, 1999, 99(21):2720-32. [PubMed 10351964]
*“ASSENT-3 Investigators. Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction,” Lancet, 2001, 358 (9282):605-13. [PubMed 11530146]

<references/>

[[Category:Pharmacology]] [[Category:Cardiology]]